<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02788006</url>
  </required_header>
  <id_info>
    <org_study_id>FFCD 1404 - REGOLD</org_study_id>
    <nct_id>NCT02788006</nct_id>
  </id_info>
  <brief_title>Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .</brief_title>
  <acronym>REGOLD</acronym>
  <official_title>Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter prospective phase II study evaluating regorafenib in older patients with&#xD;
      metastatic colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">September 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor control rate</measure>
    <time_frame>2 months</time_frame>
    <description>Number of patients with a complete or partial response or in stability 2 months after the beginning of treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Colorectal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Regorafenib 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib 160 mg</intervention_name>
    <arm_group_label>Regorafenib 160 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Metastatic colorectal cancer with histological proof&#xD;
&#xD;
          -  Measurable disease according RECIST 1.1&#xD;
&#xD;
          -  Age ≥ 70 years&#xD;
&#xD;
          -  ECOG ≤ 1&#xD;
&#xD;
          -  Biological values Haemoglobin ≥ 9 g/dL, PNN ≥ 1500/mm3, platelets≥ 100 000/mm3,&#xD;
             bilirubin ≤ 1,5N, ASAT, ALAT et PAL ≤ 2,5N (≤ 5N if hepatic metastases), lipase ≤1,5N,&#xD;
             TP≥ 70%, Creatinine clairance ≥ 30 mL/min&#xD;
&#xD;
          -  Patient without response to 5FU chemotherapy or anti-vegf treatment or anti EGFR&#xD;
             treatment (if RAS wild-type), in progression during this treatment or treatment&#xD;
             stopped because of toxicities&#xD;
&#xD;
          -  Geriatric Questionnaires answered&#xD;
&#xD;
          -  Life-expectancy ≥ 3 months&#xD;
&#xD;
          -  Informed Consent Signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not able to swallow tablets (crushed tablets are not allowed)&#xD;
&#xD;
          -  Previous treatment with regorafenib or other multikinase treatment&#xD;
&#xD;
          -  Other cancer during the last 5 years, excepted in-situ cervix cancer, skin cancer non&#xD;
             melanoma and cancer of the bladder curatively treated&#xD;
&#xD;
          -  Radiotherapy: with extended fields in the last 4 weeks, with limited fields in the&#xD;
             last 2 weeks previous inclusion&#xD;
&#xD;
          -  Toxicity &gt; grade 1 not resolved with previous treatment&#xD;
&#xD;
          -  Major surgery in the 28 days before the inclusion&#xD;
&#xD;
          -  Non cicatrized injury, ulcer or bone fracture&#xD;
&#xD;
          -  Congestive Cardiac insufficiency classe &gt;2 (NYHA)&#xD;
&#xD;
          -  Unstable angor in the last 3 months&#xD;
&#xD;
          -  Myocardial Infraction in the 6 months before inclusion&#xD;
&#xD;
          -  HTA not controlled&#xD;
&#xD;
          -  Pheochromocytome&#xD;
&#xD;
          -  Arterial or venous thromboembolism in the past 6 months&#xD;
&#xD;
          -  Infection of grade &gt; 2&#xD;
&#xD;
          -  VIH infection&#xD;
&#xD;
          -  B or C hepatitis necessiting a specific treatment&#xD;
&#xD;
          -  Cirrhosis&#xD;
&#xD;
          -  Suspicion of brain metastasis or brain metastasis&#xD;
&#xD;
          -  Haemorraghe ofgrade &gt;3 in the last weeks&#xD;
&#xD;
          -  Symptomatic Pulmonary fibrosis&#xD;
&#xD;
          -  Proteinuria &gt; grade 3&#xD;
&#xD;
          -  Malabsorption&#xD;
&#xD;
          -  Allergy know to the treatment or to one similar treatment or to one treatment&#xD;
             component&#xD;
&#xD;
          -  Systemic anti-cancer drug during the study or the the last 4 weeks&#xD;
&#xD;
          -  Concomitant treatment with CYP3A4 inhibitor or inductor or with UGT1A9 inhibitor&#xD;
&#xD;
          -  Social, psychological or medical condition which can interfere with the study&#xD;
             participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas APARICIO, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Avicenne BOBIGNY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Bacless</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oncologie et Radiothérapie</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Cap d'Or</name>
      <address>
        <city>La Seyne Sur Mer</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caluire et Cuire - Infirmerie Protestante de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud (HCL) - Pierre Benite</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR - Service HGE</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Annecy Genevois</name>
      <address>
        <city>Pringy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital privé</name>
      <address>
        <city>Villeneuve D'Ascq</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Aparicio T, Darut-Jouve A, Khemissa Akouz F, Montérymard C, Artru P, Cany L, Romano O, Valenza B, Le Foll C, Delbaldo C, Falandry C, Norguet Monnereau E, Ben Abdelghani M, Smith D, Rinaldi Y, Père Verge D, Baize N, Maillard E, Dohan A, Des Guetz G, Pamoukdjian F, Lepage C. Single-arm phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients over 70 with previously treated metastatic colorectal adenocarcinoma FFCD 1404 - REGOLD. J Geriatr Oncol. 2020 Nov;11(8):1255-1262. doi: 10.1016/j.jgo.2020.04.001. Epub 2020 Apr 22.</citation>
    <PMID>32334940</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 20, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2016</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

